MARKET

PFE

PFE

Pfizer
NYSE

Real-time Quotes | Nasdaq Last Sale

52.23
+0.59
+1.14%
Opening 14:31 07/06 EDT
OPEN
51.64
PREV CLOSE
51.64
HIGH
52.80
LOW
51.59
VOLUME
11.30M
TURNOVER
238.26M
52 WEEK HIGH
61.71
52 WEEK LOW
38.93
MARKET CAP
293.06B
P/E (TTM)
11.78
1D
5D
1M
3M
1Y
5Y
BRIEF-Australia's TGA Grants Provisional Determinations To Pfizer For Omicron COVID-19 Vaccines
BRIEF-Australia's TGA Grants Provisional Determinations To Pfizer For Omicron COVID-19 Vaccines
Reuters · 14h ago
BRIEF-Touchlight Says Signs Patent License Agreement With Pfizer For The Use Of dbDNA For The Manufacture Of mRNA-Based Vaccines
BRIEF-Touchlight Says Signs Patent License Agreement With Pfizer For The Use Of dbDNA For The Manufacture Of mRNA-Based Vaccines
Reuters · 20h ago
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Pfizer (PFE) closed at $51.64, marking a -1.28% move from the previous day.
Zacks · 21h ago
Omicron sub-variants BA.4, BA.5 make up 70% of COVID variants in U.S. - CDC
Omicron sub-variants BA.4, BA.5 make up 70% of COVID variants in U.S. - CDC
Reuters · 23h ago
Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant
With the U.S. FDA saying that COVID-19 booster vaccines need to include <a href="https://seekingalpha.com/news/3853297-fda-requests-manufacturers-to-update-vaccines-for-latest-omicron-subvariants?utm_medium=referral&utm_source=webull.com" t...
Seekingalpha · 1d ago
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
Pfizer stock crashed into its 50-day line Tuesday after Germany's CureVac sued its Covid vaccine partner, BioNTech, for patent infringement.
Investor's Business Daily · 1d ago
IMX score falls to 'moderate low' level in June
June TD Ameritrade Investor Movement Index: 5.10</stron...
Seekingalpha · 1d ago
Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?
Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.
Zacks · 1d ago
More
No Data
Learn about the latest financial forecast of PFE. Analyze the recent business situations of Pfizer through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 26 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

15.38%Strong Buy
34.62%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PFE stock price target is 58.62 with a high estimate of 75.00 and a low estimate of 46.00.
High75.00
Average58.62
Low46.00
Current 52.11
EPS
Actual
Estimate
0.470.941.401.87
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 3.51K
Institutional Holdings: 3.89B
% Owned: 69.39%
Shares Outstanding: 5.61B
TypeInstitutionsShares
Increased
1.33K
202.99M
New
140
15.84M
Decreased
1.30K
153.08M
Sold Out
176
49.15M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.15%
Pharmaceuticals & Medical Research
-0.12%
Key Executives
Chairman/Chief Executive Officer/Director
Albert Bourla
Chief Financial Officer/Executive Vice President
David Denton
Corporate Executive
Angela Hwang
Executive Vice President/Chief Technology Officer
Lidia Fonseca
Executive Vice President/Chief Compliance Officer/Chief Risk Officer
Rady Johnson
Executive Vice President/General Counsel
Douglas Lankler
Executive Vice President
William Carapezzi
Executive Vice President
Aamir Malik
Executive Vice President
Michael Mcdermott
Executive Vice President
Payal Sahni
Executive Vice President
Sally Susman
Chief Scientific Officer
Mikael Dolsten
Lead Director/Independent Director
Shantanu Narayen
Independent Director
Ronald Blaylock
Independent Director
Susan Desmond-Hellmann
Independent Director
Joseph Echevarria
Independent Director
Scott Gottlieb
Independent Director
Helen Hobbs
Independent Director
Susan Hockfield
Independent Director
Dan Littman
Independent Director
Suzanne Nora Johnson
Independent Director
James Quincey
Independent Director
James Smith
No Data
No Data
About PFE
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company offers therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator in development for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. The Company's medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.

Webull offers kinds of Pfizer Inc. stock information, including NYSE:PFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PFE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PFE stock methods without spending real money on the virtual paper trading platform.